Breath Biotics

AOR08380

Supports a healthy oral environment and combats bad breath

  • Naturally sweetened with a fresh, minty taste
  • High dose of the patented oral probiotic strain BLIS™ K12
  • Clinically studied to promotes a healthy oral microbiome
Gluten Free
Non-GMO
Vegetarian

$44.96 or subscribe and get 20% off

In stock

Choose a subscription plan:

An estimated 1 out of every 4 individuals experience halitosis regularly. There are several issues that may trigger bad breath–poor oral hygiene and the buildup of bacteria being at the top of the list. But bad breath may be the result of a number of other factors as well such as exposure to malodorous foods, an infection, or a deeper, more systemic medical concern.

Breath odor itself relates to volatile compounds with a high sulfur content that are produced by gram-negative bacteria on the tongue or between and around teeth. Halitosis can be transient (from sulfuric foods, tobacco products, or dry mouth) or it can persist.*

Cleaning the tongue, by brushing or with mouthwashes, may remove some of the offensive compounds (food remnants, dead cells, etc.) that the bacteria feed on. It may also clear away the bacteria themselves or help mask the odor for a period of time. Treatment of the underlying cause, however, is ultimately the best practice.

When combating halitosis, the first step should be determining whether the oral microbiota are healthy. The Breath Biotics formula with BLIS™ K12 contains a patented strain of the probiotic Streptococcus salivarius K12, which helps ensure healthy oral microflora, therefore reducing the bacteria that cause both bad breath and sore throat.

Breath Biotics offers the support you need to target the underlying cause of halitosis and promote clean and fresh breath. BLIS™ K12 is a registered trademark of Blis Technologies New Zealand.

*Persistent halitosis may indicate a more serious condition and it is best to consult with a doctor for a course of treatment.

Discussion

Breath Biotics is Streptococcus salivarius K12, an oral probiotic which helps promote fresh breath and oral health.

Guarantee

AOR™ guarantees that all ingredients have been declared on the label. Made without wheat, gluten, sesame seeds, sulfites, mustard, eggs or shellfish.

Adult Dosage

For oral health take 1-2 lozenges daily for a minimum of 10 days. Suck lozenge for 5 minutes, then swallow. Before taking the first lozenge of the day, rinse mouth with an antimicrobial mouthwash. Take at least 2-3 hours before or after antibiotics. For halitosis (bad breath) take 4 lozenges daily for a minimum of 3 days. Once open, store in the refrigerator to maintain optimal potency.

Cautions

Consult your physician before use if you are pregnant, lactating, have a medical condition, or are taking any medication. Keep out of reach of children.

Source

BLIS K12™ is a patented probiotic strain (Streptococcus salivarius K12)

Main Applications
  • Bad breath
  • Oral health
  • Sore throat
Disclaimer

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Serving Size: 1 Lozenge
Amount Per Serving
% Daily Value
BLIS K12™ǂ (Streptococcus salivarius K12)
1 billion CFU¶

† Daily Value not established

ǂ BLIS K12™ is a registered trademark of Blis Technologies New Zealand.

¶ CFU: Colony-forming units

Other Ingredients: isomalt, maltodextrin, monk fruit extract, starch, gum Arabic, hyprolose, trehalose, lacitol, natural flavor (wintergreen, peppermint) and sodium stearyl fumarate.

Burton, J.P., et al., A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol, 2006. 100(4): p. 754-64.

Burton, J. P., S. Cowley, et al. (2011). “Evaluation of safety and human tolerance of the oral
probiotic Streptococcus salivarius K12: A randomized, placebo-controlled, double-blind study.” Food Chem Toxicol 49(9): 2356-2364.

Chilcott, C., et al., Elevated levels of interferon gamma in human saliva following ingestion of
Streptococcus salivarius K12, in Joint New Zealand an Australian Microbiological Societies
Annual Meeting. 2005: Dunedin.

Dierksen, K. P., C. J. Moore, et al. (2007). “The effect of ingestion of milk supplemented with
salivaricin A-producing Streptococcus salivarius on the bacteriocin-like inhibitory activity of
streptococcal populations on the tongue.” FEMS Microbiol Ecol 59(3): 584-591.

Dierksen, K. P., and J. Tagg. 2000. The influence of indigenous bacteriocin-producing
Streptococcus salivarius on the acquisition of Streptococcus pyogenes by primary school
children in Dunedin, New Zealand. p. 81-85. In D. R. Martin and T. J. (ed.), Streptococci and
streptococcal diseases entering the new millennium. Securacopy, Auckland.
Di Pierro F, Colombo M, Zanvit A, Risso P, Rottoli AS. Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug Healthc Patient Saf. 2014 Feb 13;6:15-20. doi: 10.2147/DHPS.S59665. eCollection 2014.
Fantinato V, Jeorge AOA, Shimizu MT. 1999. Production of bacteriocin-like inhibitory substances (BLIS) by Streptococcus salivarius strains isolated from the tongue and throat of children with and without sore throat. Rev. Microbiol. 30:332-34.

Kreth, J., Giacaman, R. A., Raghavan, R. and Merritt, J. (2016), The Road Less Traveled – Defining molecular commensalism with Streptococcus sanguinis. Mol oral Microbiol. Accepted Author Manuscript. doi:10.1111/omi.12170
Marchetti E, Tecco S, Santonico M, Vernile C, Ciciarelli D, Tarantino E, Marzo G, Pennazza G. Multi-Sensor Approach for the Monitoring of Halitosis Treatment via Lactobacillus brevis (CD2)-Containing Lozenges–A Randomized, Double-Blind Placebo-Controlled Clinical Trial. Sensors (Basel). 2015 Aug 10;15(8):19583-96. doi: 10.3390/s150819583.
Power DA, Burton JP, Chilcott CN, PJ Dawes and Tagg JR (2008) Preliminary Investigations of the Colonisation of Upper Respiratory Tract Tissues of Infants Using a Paediatric Formulation of the Oral Probiotic Streptococcus salivarius K12. European Journal of Clinical Microbiology & Infectious Diseases 27: 1261 -3.

Walls, T., D. Power, and J. Tagg, Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? J Med Microbiol, 2003. 52(Pt 9): p. 829-33.

Wescombe PA, Hale JD, Heng NC, Tagg JR. Developing oral probiotics from Streptococcus salivarius. Future Microbiol. 2012 Dec;7(12):1355-71. doi: 10.2217/fmb.12.113.

Wescombe, P. A., Upton, M., Dierksen, K. P., Ragland, N. L., Sivabalan, S., Wirawan, R. E., Inglis,
M. A., Moore, C. J., Walker, G. V., Chilcott, C. N., Jenkinson, H. F., Tagg, J. R. (2006). Production
of the Lantibiotic Salivaricin A and Its Variants by Oral Streptococci and Use of a Specific
Induction Assay To Detect Their Presence in Human Saliva. Appl. Environ. Microbiol. 72: 1459- 1466